Group One Trading
XERS icon

Group One Trading’s Xeris Biopharma Holdings XERS Stock Holding History

Group One Trading’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.9K Sell
5,500
-6,600
-55% -$43.8K ﹤0.01% 5616
2025
Q4 		$95K Sell
12,100
-2,900
-19% -$22.8K ﹤0.01% 5049
2025
Q3 		$122K Buy
15,000
+4,400
+42% +$29.2K ﹤0.01% 5154
2025
Q2 		$49.5K Sell
10,600
-11,200
-51% -$51.3K ﹤0.01% 5582
2025
Q1 		$120K Sell
21,800
-25,400
-54% -$103K ﹤0.01% 4456
2024
Q4 		$160K Sell
47,200
-16,000
-25% -$51.5K ﹤0.01% 4110
2024
Q3 		$180K Buy
63,200
+41,300
+189% +$106K ﹤0.01% 3714
2024
Q2 		$49.3K Sell
21,900
-28,800
-57% -$58K ﹤0.01% 4535
2024
Q1 		$112K Buy
50,700
+45,400
+857% +$117K ﹤0.01% 4061
2023
Q4 		$12.5K Sell
5,300
-2,400
-31% -$4.43K ﹤0.01% 6068
2023
Q3 		$14.3K Sell
7,700
-5,900
-43% -$13.5K ﹤0.01% 6127
2023
Q2 		$35.6K Buy
13,600
+9,100
+202% +$23.2K ﹤0.01% 5540
2023
Q1 		$7.33K Sell
4,500
-1,100
-20% -$1.38K ﹤0.01% 6117
2022
Q4 		$7.45K Sell
5,600
-3,200
-36% -$4.52K ﹤0.01% 6152
2022
Q3 		$14K Buy
8,800
+1,600
+22% +$2.65K ﹤0.01% 6308
2022
Q2 		$11K Buy
7,200
+5,400
+300% +$11.4K ﹤0.01% 6721
2022
Q1 		$5K Sell
1,800
-152,100
-99% -$372K ﹤0.01% 7483
2021
Q4 		$451K Buy
153,900
+130,700
+563% +$282K ﹤0.01% 4251
2021
Q3 		$57K Sell
23,200
-39,500
-63% -$115K ﹤0.01% 6451
2021
Q2 		$255K Buy
62,700
+28,600
+84% +$109K ﹤0.01% 4964
2021
Q1 		$154K Buy
34,100
+8,400
+33% +$45.3K ﹤0.01% 5269
2020
Q4 		$126K Buy
25,700
+23,900
+1,328% +$120K ﹤0.01% 4398
2020
Q3 		$11K Buy
+1,800
New +$7.2K ﹤0.01% 5395
2020
Q2 		– Sell
-300
Closed -$1K – 6245
2020
Q1 		$1K Hold
300
– – ﹤0.01% 5119
2019
Q4 		$2K Hold
300
– – ﹤0.01% 4926
2019
Q3 		$3K Buy
+300
New +$3.37K ﹤0.01% 4878

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading's XERS Position: Q1 2026 in Review

Group One Trading increased its Xeris Biopharma Holdings (XERS) stake by 77% in Q1 2026, buying an estimated $627K and bringing the position to 218,145 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2485.

Group One Trading first reported a position in XERS in Q3 2019 and has held it in 12 quarters since. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Group One Trading held 218,145 shares of Xeris Biopharma Holdings worth $1.27M as of Q1 2026.
  • Group One Trading bought 94,584 Xeris Biopharma Holdings shares in Q1 2026, an estimated $627K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #2485 holding.
  • Group One Trading first reported a position in Xeris Biopharma Holdings in Q3 2019 and has held it in 12 quarters since.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.